MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40292-024-00689-3

Медицинская библиотека · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2024

Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysis.

Habboush Shady, Kagita Navyamani V, Gadelmawla Ahmed F, Elmoursi Ahmed, Merza Nooraldin, Abdo Ahmed A, Zahran Al Hussein M, Eldeib Moustafa, Almarghany Alsayed A, Abdelfadil Mohamed M, Abdelkarim Mohamed A, Shawky Islam, Mohammed Omar M, Alharran Abdullah, Ali Mahmoud M, Elbardisy Shereef

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

INTRODUCTION

Hypertension and dyslipidemia are common contributors to cardiovascular disease (CVD), often occurring together. Effectively Managing both is key to reducing mortality and morbidity, but complex regimens reduce adherence.

AIM: This study investigated the comparative efficacy and safety of a three-drug regimen (TAR) containing telmisartan, amlodipine, and rosuvastatin against two-drug combinations (TA and TR) for managing hypertension and dyslipidemia.

METHODS

We searched PubMed, Web of Science, Cochrane, Embase, and Scopus databases for relevant articles matching our inclusion criteria. Following the application of inclusion criteria, four studies were selected for qualitative analysis and four studies for meta-analysis.

RESULTS

Our analysis showed TAR [n = 155] significantly reduced mean systolic blood pressure (MSSBP) at week 4 compared to TR (n = 163) (MD = -15.65 mmHg) and TA (MD = -4.63 mmHg). TAR also showed superiority over all groups (TR [n = 163], TA [n = 162]) in MSSBP reduction. For low-density lipoprotein-cholesterol (LDL-C), TAR only showed a significant difference at week 4 compared to TA (MD = -86.41 mg/dL), with no difference between TAR and TR at either week 4 or 8.

CONCLUSION

Our findings suggest that TAR may be a safe and effective therapeutic option for the concurrent management of hypertension and dyslipidemia. However, there is no significant difference regarding adverse events between both arms.

Для цитирования: Habboush Shady, Kagita Navyamani V, Gadelmawla Ahmed F, Elmoursi Ahmed, Merza Nooraldin, Abdo Ahmed A, Zahran Al Hussein M, Eldeib Moustafa, Almarghany Alsayed A, Abdelfadil Mohamed M, Abdelkarim Mohamed A, Shawky Islam, Mohammed Omar M, Alharran Abdullah, Ali Mahmoud M, Elbardisy Shereef. Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysis.. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension. 2024. DOI: 10.1007/s40292-024-00689-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.